AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31782814
Drug: Budesonide (BD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (BD; 256 μg) plus Montelukast (MNT; 10 mg) for 2 weeks
Trial: 30291868
Drug: MRI-PDFF (MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-PDFF (MR imaging estimated proton density fat fraction) after 24 weeks of treatment with selonsertib
Trial: 25052217
Drug: Intravenous piracetam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous piracetam (2000 mg)
Trial: 21700922
Drug: Prism adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism adaptation (PA) therapy - repetitive pointing with prism glasses inducing rightward optical shift, twice daily, 5 days per week, for 2 weeks.
Trial: 15936046
Drug: Small sized
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small sized compound letters (where global shape was more salient)
Trial: 12972982
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg TRH
Trial: 3958225
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of triazolam 0.5 mg
Trial: 3958225
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of triazolam 0.5 mg
Trial: 26670129
Drug: Elastic compression
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic compression stocking (ECS) therapy for 2 years
Trial: 26670129
Drug: Elastic compression
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic compression stocking (ECS) therapy with ability to put on independently
Trial: 26670129
Drug: ECS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECS therapy
Trial: 20113765
Drug: Once-weekly supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly supervised pulmonary rehabilitation (n=15)
Trial: 20113765
Drug: Twice-weekly supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly supervised pulmonary rehabilitation (n=15)
Trial: 8550853
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) 1,000 mg/m2 intravenously over 24 h
Trial: 6122111
Drug: Oral diazoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazoxide
Trial: 6122111
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (diuretic + beta‐adrenoceptor blocker + hydralazine + prazosin)
Trial: 23803871
Drug: Ketamine (0.54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.54 mg/kg within 30 min)
Trial: 12510415
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 mg twice a day
Trial: 9856708
Drug: Systemic lidocaine
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic lidocaine (2 mg/kg bolus followed by 2 mg x kg(‐1) x h(‐1) infusion for 50 min)
Trial: 9856708
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional anesthesia with lidocaine (40 ml, 0.05%)
Trial: 9856708
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (systemic and regional lidocaine)
Trial: 553663
Drug: Chlorpheniramine inhalation
RxNorm normalized name: chlorpheniramine / phenylephrine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine inhalation
Trial: 25044531
Drug: SRP+AZM (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP+AZM (500 mg oral delivery × 3 days)
Trial: 23083066
Drug: CHMP 3×2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHMP 3×2 tablets per day
Trial: 23083066
Drug: CHMP 2×2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHMP 2×2 tablets per day
Trial: 23083066
Drug: Placebo (3×2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3×2 tablets per day)
Trial: 20215608
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent influenza vaccine
Trial: 8277200
Drug: Cold-adapted vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted vaccine
Trial: 29069415
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccines (PCVs)
Trial: 26565716
Drug: Dapivirine (0.05%)
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine (0.05%) gel
Trial: 25948671
Drug: Lowest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quartile of SFA intake (<17.39 g/d)
Trial: 23994919
Drug: Reosorbilact (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reosorbilact (200-400 ml intravenously for 20 days)
Trial: 12804135
Drug: Plasmid DNA
RxNorm normalized name: Immunotherapeutic vaccine consisting of pAc/emm55, a plasmid DNA (pDNA), which codes for a modified immunogenic, streptococcal Emm55 protein, complexed with in vivo-jetPEI¬Æ polymer-based reagent linear polyethylenimine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmid DNA encoding gp100 administered intramuscularly (n = 12)
Trial: 405412
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (N)
Trial: 30345658
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages consisting of multiple-choice questions with links to online material
Trial: 21227600
Drug: Δ⁹‐THC (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ⁹‐THC (30 mg)
Trial: 3017596
Drug: Nabilone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (1 mg)
Trial: 11499328
Drug: Tretinoin 0.1%
RxNorm normalized name: TRETINOIN 0.1% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.1% gel microsponge
Trial: 9990419
Drug: Tretinoin 0.025%
RxNorm normalized name: TRETINOIN 0.025% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.025% gel
Trial: 11499328
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel (once-daily)
Trial: 11499328
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel (alternate-day)
Trial: 2865009
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine cream 1%
Trial: 27989639
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (ET)
Trial: 21872140
Drug: Management guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management guided by daily noninvasive estimated LVEDP monitoring (Group I, open)
Trial: 7533030
Drug: Doxazosin Mesylate
RxNorm normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin Mesylate (1 to 2 mg and from 2 to 4 mg over 45 days)
Trial: 30044899
Drug: Cyclosporine 100
RxNorm normalized name: cyclosporine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 100 mg twice daily for 5 days with Amenamevir 400 mg and 1200 mg single doses
Trial: 26850023
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives for adherence to anti-psychotic medication
Trial: 22947249
Drug: Low-dose b240
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose b240 (2 × 10^9 cells)
Trial: 22947249
Drug: High-dose b240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose b240 (2 × 10^10 cells)
Trial: 22947249
Drug: b240 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b240 (both doses)
Trial: 10851674
Drug: Combined surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined surgery and radiation therapy
Trial: 3924081
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (Transiderm‐Nitro 5)
Trial: 31888575
Drug: Mexican Guideline
RxNorm normalized name: Mexican tea pollen extract
DrugBank: Chenopodium ambrosioides pollen (DB10479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexican Guideline Daily Allowances (GDA)
Trial: 27213837
Drug: Antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive therapy (AT)
Trial: 22956219
Drug: Lacteol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacteol (2 capsules/day) for 4 weeks
Trial: 16080280
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg diclofenac epolamine plaster (reference preparation)
Trial: 12695914
Drug: Glycerol hyperhydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol hyperhydration (1.2 g kg(‐1) body mass glycerol mixed with 21 ml kg(‐1) body mass flavoured water)
Trial: 15673385
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic drug therapy
Trial: 8987192
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine immunization scheme and a booster dose at 15 months of age
Trial: 3881710
Drug: Triple-dose cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose cefotaxime
Trial: 30321667
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (initial bolus dose of 2500 μg cholecalciferol followed by 100 μg cholecalciferol/d)
Trial: 22305377
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg valganciclovir
Trial: 22305377
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg valganciclovir
Trial: 11392580
Drug: omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 40 mg once a day for 8 weeks
Trial: 8064597
Drug: Piroxicam (Feldene,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (Feldene, 20 mg daily)
Trial: 24923656
Drug: 1-g mesalazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g mesalazine suppository
Trial: 9059138
Drug: Sulphasalazine 2-3
RxNorm normalized name: sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphasalazine 2-3 g per day (n = 37)
Trial: 8448068
Drug: Isradipine sustained
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine sustained release (I-SRO) 5 mg PM
Trial: 17110413
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C (2 g) and E (400 IU) given 2 h before a second dive
Trial: 15288288
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (12 Gy) brachytherapy
Trial: 15785149
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (INR 2.0-3.0)
Trial: 18372254
Drug: FSH-only preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH-only preparations following a low-dose step-up protocol
Trial: 12850192
Drug: p53 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: p53 gene therapy in combination with standard chemotherapy
Trial: 8990505
Drug: Topical R-85355
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical R-85355
Trial: 1473919
Drug: Ioxaglate administered
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate administered intravenously
Trial: 24477835
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (5 g day(‐1) of powdered 1:0.5:0.5 leucine:isoleucine:valine)
Trial: 11468025
Drug: Calculated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated dose (CD) using Bayesian methodology
Trial: 11468025
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose (LD) of 25 mg/kg body weight
Trial: 11468025
Drug: Calculated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated dose (CD)
Trial: 11468025
Drug: Calculated dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated dose (CD) in ventilated patients
Trial: 9706734
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) adjunctive therapy
Trial: 8156738
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic factor (10 ng min‐1 100 ml‐1 forearm volume)
Trial: 8156738
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (equipotent vasodilator dose)
Trial: 3279775
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg per day of ketoconazole
Trial: 3279775
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg per day of ketoconazole
Trial: 28640136
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of physical activity (PPA)
Trial: 18342223
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg the day before (>or=15 h) and 600 mg the morning of the procedure (>or=2 h) (Group C)
Trial: 18342223
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg the day before (>or=15 h) + 75 mg the morning of the procedure (Group A)
Trial: 9255192
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment with iNO after HFOV failure
Trial: 9255192
Drug: Crossover treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover treatment with HFOV after iNO failure
Trial: 3625231
Drug: Single 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2 h infusion of 500 mg of 9.2.27
Trial: 3625231
Drug: Five daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five daily 2 h infusions of 100 mg of 9.2.27
Trial: 3625231
Drug: Interruption in
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interruption in therapy for 4 weeks
Trial: 3625231
Drug: Initial infusions
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial infusions of 500 mg of 9.2.27
Trial: 3625231
Drug: Monitoring antiglobulin
RxNorm normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring antiglobulin levels during therapy
Trial: 31547827
Drug: Primaquine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (0.5 mg/kg/day for 7-9 days)
Trial: 28962948
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with thoracic radiotherapy (50 Gy in 25 fractions) and five cycles of weekly paclitaxel (50 mg/m2) and cisplatin (25 mg/m2), followed by two additional cycles of paclitaxel (175 mg/m2) plus cisplatin (80 mg/m2) at 3-week intervals.
Trial: 28962948
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with four cycles of adjuvant paclitaxel (175 mg/m2) and carboplatin (AUC = 5.5) every 3 weeks.
Trial: 21390165
Drug: Fentanyl 20
RxNorm normalized name: fentaNYL 200 mcg buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 20 µg
Trial: 21390165
Drug: Sufentanil 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2.5 µg
Trial: 20032609
Drug: Bethanechol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol administration during radiotherapy
Trial: 18693589
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC‐40) 40 mg instilled within 30 minutes of TUR
Trial: 310412
Drug: Gastrozepin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrozepin therapy
Trial: 19336728
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg/wk
Trial: 19336728
Drug: Bicalutamide 100
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 100 mg/wk
Trial: 17899572
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal gel
Trial: 11916619
Drug: Antibiotic-soak group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-soak group (gentamicin solution for approximately 2 min)
Trial: 9785777
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and fentanyl (group P, n = 107)
Trial: 9785777
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and fentanyl (group P)
Trial: 2715803
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy (CT) - six courses
Trial: 1052105
Drug: Tinidazole (Fasigyn-Pfizer)
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole (Fasigyn-Pfizer) - 2 grammes as a single oral dose
Trial: 31524770
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acid granules (12 g of branched-chain amino acid)
Trial: 11355560
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg single dose)
Trial: 7803947
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitors
Trial: 8476408
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy
Trial: 8078530
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg per day for 8 weeks, then 6 mg per day for 2 weeks)
Trial: 8078530
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg per day for 2 weeks, then gradually reduced to 5 mg per day)
Trial: 829223
Drug: Local VM
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local VM 26 chemotherapy after TUR
Trial: 17393216
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day DHA-rich fish oil
Trial: 8534465
Drug: Dezocine 6
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dezocine 6 mg IV
Trial: 8534465
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg IV
Trial: 7003457
Drug: Levamisole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (50 mg t.i.d. for 3 consecutive days every 2 weeks)
Trial: 31270173
Drug: MenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenB vaccine (Bexsero)
Trial: 31270173
Drug: Other meningococcal
RxNorm normalized name: other meningococcal monovalent purified polysaccharides antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other meningococcal vaccines (57 adults)
Trial: 28027445
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment coupled with usual lactation consultations
Trial: 26391602
Drug: 2.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day oral mesalazine
Trial: 26391602
Drug: 4.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 g/day oral mesalazine
Trial: 23206372
Drug: Two-phase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-phase treatment starting in mixed dentition
Trial: 19237900
Drug: NIV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIV with low internal volume mask (163 mL)